bild
21369039
One of the buildings of the headquarters of Gilead Sciences, Inc. in Foster City, CA, on April 30, 2020. Its drug, Remdesivir, may be near regulatory authorization in the U.S. as a COVID-19 treatment following early data readouts for a pair of clinical trial. (KEYSTONE/LAIF/Frederic Neema)
Instruktionen
COPYRIGHTPFLICHTIG _(86.13 MB vorhanden)_
Lizenz
Rights Managed
Erstellungsdatum
20200430
Ort
USA VEREINIGTE STAATEN AMERIKA
Credit
KEYSTONE
Source
LAIF
Byline
FREDERIC NEEMA
Grösse
6720 x 4480 px
Dateityp
JPEG